Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 538-547

  Burden, Roberta E ^a   Snoddy, Philip ^b   Buick, Richard J ^b   Johnston, James A ^a   Walker, Brian ^a   Scott, Christopher J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b FUSION ANTIBODIES LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN L; CATHEPSIN S; CHIMERIC PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PROTEINASE;

ARTICLE; ASTROCYTOMA; ATTENUATION; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL ASSAY; CELL INVASION; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INHIBITION; ELASTOLYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MICROENVIRONMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; SPECIES; TUMOR CELL;

BASE SEQUENCE; CATHEPSINS; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DNA PRIMERS; HUMANS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 41649103656     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0528     Document Type: Article

References (50)

1. Rawlings ND, Tolle DP, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res 2004;32:D160-4.
2. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003;3:472-82.
3. Bryant P, Ploegh H. Class II MHC peptide loading by the professionals. Curr Opin Immunol 2004;16:96-102.
4. Yasuda Y, Kaleta J, Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005;57:973-93.
5. Chapman HA, Jr., Munger JS, Shi GP. The role of thiol proteases in tissue injury and remodeling. Am J Respir Crit Care Med 1994;150:S155-9.
6. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997;59:63-88.
7. Mach L, Mort JS, Glossl J. Maturation of human procathepsin B. proenzyme activation and proteolytic processing of the precursor to the mature proteinase, in vitro, are primarily unimolecular processes. J Biol Chem 1994;269:13030-5.
8. Maubach G, Schilling K, Rommerskirch W, et al. The inhibition of cathepsin S by its propeptide-specificity and mechanism of action. Eur J Biochem 1997;250:745-50.
9. Guay J, Falgueyret JP, Ducret A, Percival MD, Mancini JA. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides. Eur J Biochem 2000;267:6311-8.
10. Billington CJ, Mason P, Magny MC, Mort JS. The slow-binding inhibition of cathepsin K by its propeptide. Biochem Biophys Res Commun 2000;276:924-9.
11. Carmona E, Dufour E, Plouffe C, et al. Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases. Biochemistry 1996;35:8149-57.
12. Burden RE, Snoddy P, Jefferies CA, Walker B, Scott CJ. Inhibition of cathepsin L-like proteases by cathepsin V propeptide. Biol Chem 2007;388:541-5.
13. Premzl A, Zavasnik-Bergant V, Turk V, Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res 2003;283:206-14.
14. Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growthand angiogenesis during multistage tumorigenesis. Cancer Cell 2004;5:443-53.
15. Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006;20:543-56.
16. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000;291:113-35.
17. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
18. Flannery T, Gibson D, Mirakhur M, et al. The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol 2003;163:175-82.
19. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 1988;61:201-301.
20. Werle B, Staib A, Julke B, et al. Fluorometric microassays for the determination of cathepsin L and cathepsin S activities in tissue extracts. Biol Chem 1999;380:1109-16.
21. Lecaille F, Weidauer E, Juliano MA, Bromme D, Lalmanach G. Probing cathepsin K activity with a selective substrate spanning its active site. Biochem J 2003;375:307-12.
22. Zheng XX, Steele AW, Hancock WW, et al. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol 1999;163:4041-8.
23. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-75.
24. Santamaria I, Velasco G, Cazorla M, Fueyo A, Campo E, Lopez-Otin C. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res 1998;58:1624-30.
25. Sivaparvathi M, Yamamoto M, Nicolson GL, et al. Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metastasis 1996;14:27-34.
26. Wang M, Tang J, Liu S, Yoshida D, Teramoto A. Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol 2005;71:3-7.
27. Kirschke H, Wiederanders B, Bromme D, Rinne A. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem J 1989;264:467-73.
28. Fiebiger E, Maehr R, Villadangos J, et al. Invariant chain controls the activity of extracellular cathepsin L. J Exp Med 2002;196:1263-9.
29. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:1359-66.
30. Sloane BF, Yan S, Podgorski I, et al. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol 2005;15:149-57.
31. Novinec M, Grass RN, Stark WJ, Turk V, Baici A, Lenarcic B. Interaction between human cathepsins K, L, and S and elastins: mechanism of elastinolysis and inhibition by macromolecular inhibitors. J Biol Chem 2007;282:7893-902.
32. Wang B, Sun J, Kitamoto S, et al. Cathepsin S controls angiogenesis and tumor growthvia matrix-derived angiogenic factors. J Biol Chem 2006;281:6020-9.
33. Mai J, Sameni M, Mikkelsen T, Sloane BF. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem 2002;383:1407-13.
34. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1993;1178:55-62.
35. Flannery T, McQuaid S, McGoohan C, et al. Cathepsin S expression: an independent prognostic factor in glioblastoma tumours - a pilot study. Int J Cancer 2006;119:854-60.
36. Fernandez PL, Farre X, Nadal A, et al. Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 2001;95:51-5.
37. Stabuc B, Mrevlje Z, Markovic J, Stabuc-Silih M. Expression and prognostic significance of cathepsin L in early cutaneous malignant melanoma. Neoplasma 2006;53:259-62.
38. Trinkaus M, Vranic A, Dolenc VV, Lah TT. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers 2005;20:50-9.
39. Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP. Expression of Cathepsin B and L antigen and activity is associated withear ly colorectal cancer progression. Eur J Cancer 2004;40:1610-6.
40. Rapa I, Volante M, Cappia S, Rosas R, Scagliotti GV, Papotti M. Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth. Am J Clin Pathol 2006;125:847-54.
41. Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997;57:5386-90.
42. Lindeman JH, Hanemaaijer R, Mulder A, et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004;165:593-600.
43. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
44. Bromme D, Kaleta J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr Pharm Des 2002;8:1639-58.
45. Link JO, Zipfel S. Advances in cathepsin S inhibitor design. Curr Opin Drug Discov Dev 2006;9:471-82.
46. Shinozuka T, Shimada K, Matsui S, et al. Potent and selective cathepsin K inhibitors. Bioorg Med Chem 2006;14:6789-806.
47. Katunuma N, Matsunaga Y, Himeno K, Hayashi Y. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol Chem 2003;384:883-90.
48. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases) - on the main stage of cancer? Cancer Cell 2004;5:409-10.
49. Nakagawa T, Roth W, Wong P, et al. Cathepsin L: critical role in degradation and CD4 T cell selection in the thymus. Science 1998;280:450-3.
50. Nakagawa TY, Brissette WH, Lira PD, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10:207-17.